Michigan: Michigan has not scheduled Daridorexant as a schedule IV controlled substance [Michigan Compiled Laws s. 333.7218]. Minnesota: Minnesota has not scheduled Daridorexant as a schedule IV controlled substance [Minnesota Statutes 152.02 (5)].
Summary of factual data and analytical methodologies:
The methodology was to schedule Daridorexant to conform with the federal Controlled Substances Act.
Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:
The rule schedules Daridorexant as a Schedule IV controlled substance which will not have any effect on small business.
Fiscal Estimate and Economic Analysis:
The Fiscal Estimate and Economic Impact Analysis is attached.
Effect on small business:
These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department’s Regulatory Review Coordinator may be contacted by email at Jennifer.Garrett@wisconsin.gov, or by calling (608) 266-2112. Agency contact person:
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov. TEXT OF RULE
Section 1. CSB 2.93 is created to read:
CSB 2.93 Addition of Daridorexant to schedule IV. Section 961.20 (2) (cpm), Stats., is created to read: 961.20 (2) (cpm) Daridorexant.
Section 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats. (END OF TEXT OF RULE)
